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ABSTRACT  
Purpose: To identify symptom clusters and predisposing factors associated with long-term symptoms 
and health-related quality of life (HRQOL) following radiotherapy in men with prostate cancer.  
Methods: Patient-reported outcomes (PROs) data from the Medical Research Council RT01 
radiotherapy with neoadjuvant androgen deprivation therapy (ADT) trial of 843 patients were used.  
PROs were collected over 5 years with the University of California, Los Angeles Prostate Cancer 
Index (UCLA-PCI) and the 36-Item Short-Form Health Survey (SF-36). Symptom clusters were 
explored using hierarchical cluster analysis (HCA). The association of treatment dose, baseline patient 
characteristics and early symptom clusters with the change in severity of PROs over three years was 
investigated with multivariate linear mixed effects models. 
Results: Seven symptom clusters of three or more symptoms were identified. The clusters were stable 
over time. The longitudinal profiles of symptom clusters showed the onset of acute symptoms during 
treatment for all symptom clusters and significant recovery by six months. Some clusters such as 
Physical Health and Sexual Function were adversely affected more than others by ADT, and were less 
likely to return to pre-treatment levels over time. Older age was significantly associated with 
decreased long-term Physical Function, Physical Health and Sexual Function (p<0.001). Both 
baseline and acute symptom clusters were significant antecedents for impaired function and HRQOL 
at three years.  
Conclusions: Men with poorer physical function and health prior to or during treatment were more 
likely to report poorer PROs at year three. Early assessment using PROs and lifestyle interventions 
should be employed to identify those with higher needs and provide targeted rehabilitation and 
symptom management. 
 
Keywords: Symptom clusters, Prostate cancer, Acute symptoms, Late symptoms, PROs, 
Radiotherapy, Survivorship  
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INTRODUCTION 
 Prostate cancer (PCa) survival has improved significantly over the last decade. More than 
84% of men now survive 10 years or more in the United Kingdom (UK) [1] and the number of 
survivors is growing by 3% every year [2]. Globally more than 1.1 million cases of PCa were 
recorded in 2012. This constitutes 8% of all cancers and 15% of cancers in men, making PCa the 
second most common cancer in men [3]. With increasing survival, cancer-related symptoms and 
treatment-related toxicity can impact on men’s long-term health-related quality of life (HRQOL) [4]. 
Common side-effects following prostate radiotherapy include decreased urinary, bowel and sexual 
functions and this impacts on supportive care needs of men [5]. Population based studies of long-term 
functional outcomes after PCa suggest that at 12 years from treatment 87% of men will have erectile 
dysfunction or sexual inactivity, 20% urinary incontinence and 14% bowel problems [6]. These 
figures are substantially lower in men without cancer and of a similar age (62%,6% and 7% 
respectively). Androgen deprivation therapy (ADT) is commonly used with radical radiotherapy for 
intermediate or high risk PCa. It allows for better long-term PCa control than with radiotherapy alone. 
However, it can add fatigue, hot flushes or muscle and bone loss to the spectrum of expected side-
effects [7,8].  
 The prevalence of long-term side-effects from radiotherapy depends on many factors. 
Treatment factors such as total dose or fractionation schedule and individual factors such as age, co-
morbidities or medical history (for example prior surgery) can all impact on late toxicity [9]. Patients 
undergoing radiotherapy, experience groups of symptoms called clusters in response to cancer or 
treatment. Symptom clusters were first defined in cancer by Miaskowski et al. in 2004 [10]. They are 
groups of symptoms with similar prevalence rates, and related by a common aetiology or by 
influencing similar patient outcomes. Since then the concept has served as a basis for the assessment 
and management of multiple symptoms. There has been substantive research into defining and 
identifying symptom clusters in a variety of cancers and oncology treatments [11]. Fatigue, insomnia, 
pain and depression constitute the most prevalent symptom cluster in cancer [12]. Synergy of 
symptoms in clusters has been studied and the effect on HRQOL, functional status and survival has 
been described [13,14]. 
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 In PCa there are only two studies examining symptom clusters related to the early stage 
disease or its treatment [15,16]. Maliski et al. (2008) found that fatigue and emotional distress were 
common in this group of patients and they clustered together with urinary, bowel and sexual 
symptoms [15]. Capp et al (2009) only explored rectal symptoms in their longitudinal study. They 
found that symptom clusters were stable over time and that rectal urgency and pain were the core 
drives of symptom clustering [16]. A different longitudinal study of Knapp et al. (2012) explored 
trajectories and predictors of radiotherapy-related PCa symptoms over 25 weeks [17]. They found that 
pain, fatigue, insomnia and diarrhoea were highly prevalent and related to symptom distress. Only a 
limited number of longitudinal studies are available in PCa and none report symptom clusters over a 5 
year trajectory. A limitation of studies that analyse radiotherapy-related data in a cross-sectional 
manner is that the effect of baseline symptoms on time trajectory is not considered and it may be 
attributed to radiation toxicity.  
 It is important to consider baseline symptoms when assessing treatment-related side-effects. 
This is because both baseline and acute symptoms, have been found to be a precursor of late 
symptoms. This has been termed as consequential late effects [18,19]. In addition, treatment factors 
(ADT, radiotherapy dose or fractionation) have been found to directly affect acute and late symptoms 
[20]. However, the research into treatment side-effects is now complemented by the evidence of an 
indirect effect of patient characteristics such as age, functional status or co-morbidities [21-23]. 
Despite the increasing interest and growing body of evidence, identification and prediction of long-
term symptom clusters in PCa, to establish links between symptoms and the role of other contributing 
factors, remains a challenge. Men with PCa could benefit from this through targeted symptom 
management approaches that address multiple symptoms and risk factors.  
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METHODS 
Study design and research questions 
 Longitudinal profiles of patient-reported outcomes (PROs) were explored and symptom 
clusters investigated using well-established symptom clustering methodologies [24,25]. Patterns in 
PROs data, reported up to five years post-treatment by men in the MRC RT01 clinical trial were 
investigated to study (1) which PROs were associated and formed symptom clusters. This is to 
investigate what symptom clusters are experienced by men with PCa during and post-radiotherapy. 
(2) How symptom clusters change over time. This is to investigate the effect of ADT and radiotherapy 
treatment on the trajectory of symptom clusters during the 5 years follow-up. (3) The association of 
treatment, demographics, medical history i.e. co-morbidities, and baseline and acute symptom clusters 
with the change in symptom clusters over 3 years was studied to investigate potential risk factors 
contributing to late symptom clusters.  
Dataset and patients  
 We used the MRC RT01 trial (ISRCTN47772397) which is a dataset of 843 patients [26,20]. 
It was a UK-led, multicentre, randomised controlled trial (RCT) that investigated standard (64Gy/32f) 
versus escalated (74Gy/37f) conformal radiotherapy (CFRT) with neoadjuvant ADT for patients with 
localised PCa. Eligible men had histologically confirmed PCa and prostate-specific antigen (PSA) 
<50 ng/ml, no previous PCa treatment and no significant medical history that excluded them from 
radical radiotherapy. Men were followed in the study for up to 5 years. PROs were recorded with the 
University of California, Los Angeles Prostate Cancer Index (UCLA-PCI) that also included the 
RAND 36-Item Short-Form Health Survey (SF-36). Detailed study design, patient eligibility criteria 
and main results have been published [27,28].  
Measurements and outcome variables  
 Patients’ baseline characteristics are presented in Table 1. Information includes treatment 
group, age, tumour stage, Gleason score, PSA, co-morbid conditions (diabetes, hypertension, 
inflammatory bowel, haemorrhoids) and medical history such as type of biopsy, previous pelvic 
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surgery or previous transurethral resection of the prostate (TURP). PROs were collected before 
androgen deprivation therapy (baseline), during radiotherapy (acute) and until five years post-
radiotherapy (long-term). PROs included 20 items of the UCLA-PCI [29] measuring function and 
symptom bother in the three PCa primary concern areas (urinary, bowel and sexual scales); and 36 
items of the SF-36 measured HRQOL arranged in eight multi-item scales (Physical functioning, Role 
limitations due to physical health, Role limitations due to emotional problems, Bodily pain, Vitality, 
Mental health, Social functioning and General Health) [30]. In total, 56 PROs recorded on a Likert 
scale were included in the secondary data analysis. They were collected by patient self-report at the 
following ten time points: pre-androgen deprivation therapy (pre-ADT), pre-radiotherapy (pre-RT), 
end of radiotherapy (at week 10 after the start of radiotherapy), every 6 months until year 2 (month 6, 
12, 18 and year 2) and then yearly for up-to five years (year 3, 4 and 5 after the start of radiotherapy).  
Missing data and data pre-treatment 
 The number of data missing in patient baseline characteristics is detailed in Table 1. The 
number of PROs questionnaires completed at each time point is detailed in Table 2. These missing 
data were not imputed. Numbers of single questions left unanswered in completed questionnaires 
(intermittent missing data) varied from 0.8% for Feeling tired (SF-36 Vitality Scale) to 13.4% for 
Urinary leak interfering with sex (UCLA-PCI Sexual Function Scale). Intermittent missing data were 
treated with multiple imputation, rather than using complete case analysis, to minimise the risk of 
biased results and to preserve sample size [31]. Five imputations are usually sufficient, but seven 
imputed datasets were created to further reduce the uncertainty in the prediction of missing values 
process [32]. Variables were re-scaled to a 0 to 100 scale for consistency (0 representing the worst 
outcome and 100 representing the best possible outcome), including reversing negatively worded 
questions, as recommended by the scoring manual [33].  
Symptom clusters analysis  
 Symptom clustering was performed at each point in time on completed PROs questionnaires 
(intermittent missing data imputed with multiple imputation). Similarity between symptoms was 
measured with Spearman's rho correlation coefficient (rs). To obtain pooled correlation results from 
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the seven imputed datasets, composite correlations were calculated using Fisher's z transformation 
[34]. Clustering between PROs was identified using hierarchical cluster analysis (HCA) with the 
average linkage method of cluster agglomeration. Symptom clusters were determined at a cut-off 
correlation value of  >0.60 [25].  
Multivariate linear mixed effects regression analysis 
 Multivariate linear mixed effects modelling was used to calculate the contribution of early 
symptoms and other potential risk factors such as treatment, age, medical history and other symptom 
clusters, to the change in symptom clusters over time. Composite scores of symptom clusters at three 
time points were used in longitudinal modelling: baseline (pre-ADT or pre-HT if pre-ADT was not 
collected), acute (week 10) and late (year 3). Three years’ post-radiotherapy has been used as an 
endpoint because it has been shown to be an important point in time for the recognisable development 
of late radiotherapy-related symptoms [26,35].  
Longitudinal profiles of symptom clusters were the dependent variables for the models. 
Independent variables that were investigated included baseline age, co-morbidities and medical 
history, as well as other symptom clusters that were included as fixed effects. Radiotherapy dose, time 
and individual patient variation were included in the models as random effects. Independent variables 
with preliminary significant associations of p<0.05 were retained in the final regression models. A 
statistical significance level of p<0.01 rather than 0.05 was used to account for multiple statistical 
tests that were performed. The statistical significance was estimated using likelihood ratio test [36]. 
The analysis was performed with R version 3.0.2 (R Foundation for Statistical Computing, Vienna, 
Austria).  
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RESULTS  
Symptom clusters  
 Seven symptom clusters of three or more associated symptoms were identified and named as: 
Physical Function; Physical Health; Emotional Health; Vitality; Illness Perception; Urinary Function; 
and Sexual Function. The results of symptom clustering and the number of questionnaires collected at 
each time point are presented in Table 2. Only two clusters from the SF-36 (Physical Health and 
Emotional Health) included all of the items present in the corresponding SF-36 scale. The correlation 
of bowel symptoms from the UCLA-PCI Bowel Function Scale was <0.4 and therefore not strong 
enough to form a cluster.  It is clear from the analysis that symptom clusters are not always the same 
as the scales of the UCLA-PCI or SF-36. The Urinary Function Cluster consisted of three (Urinary 
leak, Urinary control and Dripping/wetting) out of the five UCLA-PCI Urinary Function Scale 
symptoms. The remaining two symptoms (Number of pads and Urinary leak interfering with sex) did 
not exhibit high enough correlation with the three symptoms to be included in the Urinary Function 
Cluster (it was <0.2 and <0.3 respectively).  
 Symptom clusters were evaluated separately for each time point and were very similar at each 
point so relatively stable over time. In addition, there are core symptoms that were always present in a 
cluster across time. They are marked in bold in Table 2. For example, Sexual Function Cluster had 
five core symptoms (Erection ability, Orgasm ability, Quality of erections, Frequency of erections and 
Sexual function overall) and two that were present in the cluster intermittently (Sexual desire and 
Awakened with erections). There was one symptom in the Sexual Function Scale of UCLA-PCI 
(Intercourse) that was not correlated enough to belong to the Sexual Function Cluster at any time 
point.   
Longitudinal profiles of symptom clusters - trajectory of treatment and recovery 
 The longitudinal profiles of symptoms over the 5 years of follow-up are presented in Figure 
1. They document the trajectory of treatment and recovery after radiotherapy for patients with PCa. 
From these time profiles, we observe an increase in symptom intensity by week 10 which is 
represented by a peak-fall in scores. This decrease in function and HRQOL clearly corresponds to the 
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onset of acute symptoms due to radiotherapy. In relation to that, we can distinguish two types of 
trends. The first, where the onset of acute symptoms starts prior to radiotherapy, is during the period 
when men receive ADT. Clusters such as Physical Health, Vitality and Illness Perception are 
examples of this type of decline in HRQOL. However, the functional decline due to ADT is very 
prominent also for the Sexual Function Cluster. We observe that the sexual function of patients drops 
dramatically after ADT as compared to the baseline levels, and for many men it does not return to 
baseline levels even after many years post-treatment.  
 The second type of the acute functional and HRQOL decline due to treatment can be observed 
for the Physical Function, Emotional Health and Urinary Function Clusters. They were relatively 
stable during ADT and the acute decline is mainly due to radiotherapy. For these clusters, symptoms 
and HRQOL recover by 6 months post-radiotherapy, reaching higher than the pre-treatment levels. In 
addition to acute symptoms, for some symptom clusters we can also observe an increase in late 
symptoms. This decline in function and HRQOL starts after year 2 post-radiotherapy. This is 
especially prominent for the Physical Function, Emotional Health and Urinary Function Clusters.     
Risk factors and antecedents for late symptom clusters - regression analysis 
The results of regression analysis are presented in Table 3. Older age was associated with 
decreased long-term function and HRQOL for Physical Function, Physical Health and Sexual 
Function Clusters (p<0.001). For all symptom clusters, baseline and acute scores (week 10) were 
identified as significant antecedents of late symptoms at year 3. This was represented by the high 
variation between patients (p<0.001) in all seven models. Patients with more severe baseline 
symptoms had more severe acute and late symptoms. The radiotherapy dose had no statistically 
significant effect on the severity of symptom clusters over time (p=1.000) in all seven models. 
However, decreased Physical Function and Physical Health, as well as Illness Perception and Vitality 
Clusters, contributed to the increased severity of symptom clusters over time and were significant risk 
factors for late symptoms at year 3.  
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DISCUSSION 
 We studied the trajectory of symptom clusters before, during and after radiotherapy for PCa, 
by analysing symptom clusters over 5 years following radiotherapy. This study contributes to the 
limited body of research documenting symptom clusters in PCa and radical radiotherapy [37] as well 
as identifying important targets for improving patient outcomes. Symptom clusters identified were 
different to those presented in the literature so far [15,16]. We did not find the correlation of fatigue 
and mental health symptoms with PCa-specific symptoms (urinary, bowel or sexual) that was 
observed by Maliski et al. [15]. However, Vitality and Emotional Health Clusters were significant risk 
factors for the Urinary and Sexual Function Clusters as demonstrated by the regression analysis. Capp 
et al. focused on rectal toxicity in a longitudinal study. However, we did not observe a cluster 
associated with bowel dysfunction. The difference in the composition of symptom clusters between 
different studies may be due to the clustering approach or PROs tools used, or due to the differing 
treatments or population characteristics [38].  
 The composition of symptom clusters was different to that of PROs scales. Some clusters did 
not form and some of the items present in a scale were excluded from the cluster. For example, 
Number of Pads and Urinary leak interfering with sex are the two items of the Urinary Function Scale 
(UCLA-PCI) not included in the Urinary Function Cluster. We observe from Figure 1F that both of 
these symptoms are rarely reported by patients (their longitudinal profiles occupy the top part of the 
graph), and any true impact from these symptoms would be difficult to detect. Symptom clustering 
enables identification of groups of correlated symptoms that are more prevalent and more relevant to 
patients. Therefore, it allows recognition of symptom clusters specific to the type of cancer and its 
treatment which is important for appropriate symptom management [39,40]. Clinical practice often 
focuses on single symptoms [41,42]. However, the association and interaction between cancer 
symptoms should be explored [43-45]. In addition to the clinical consideration of symptoms in 
groups, symptom clusters allow a flexible and sample-specific way of analysing PROs [46]. Multiple-
item scales should be revised prior to statistical analysis and clinical utilisation of PROs. The use of 
cumulative scores based on symptom clusters rather than scales was shown to be a better predictor of 
late symptoms [47].  
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 Symptom clusters were relatively stable over time with core symptoms always present in the 
cluster. The stability of symptom clusters across the time trajectory has also been shown in other 
longitudinal studies [48,49]. However, this study is unique as there is no other study that reports PCa 
symptom clusters for as long as five years. Studies describe sentinel symptoms, which can be used as 
indicators of symptom clusters in clinical assessment [50,51]. This not only can be used in identifying 
patients at high risk of long-term symptoms, but core cluster symptoms have also been recognised as 
targets for symptom management interventions [52]. These findings are important and can lead to 
targeted prehabilitation approaches in the form of lifestyle interventions prior to ADT and 
radiotherapy. ADT reduces muscle mass and strength so it impacts on physical and functional health 
[8,53]. NICE, 2008 recommends that men on ADT receive 12 weeks of exercise intervention to 
reduce fatigue symptoms [54]. Recent systematic review and meta-analysis suggest that this is also 
beneficial for lower body strength and aerobic fitness [55]. Figure 2 illustrates potential risk factors 
that can contribute to increased radiotherapy side-effects and may influence symptom severity and 
reduce HRQOL. The effectiveness of physical rehabilitation has been shown to decrease cancer and 
treatment-related morbidity and improve late radiotherapy outcomes [56-58]. 
 Baseline and acute (end of treatment) symptom clusters were associated with decreased long-
term function and HRQOL in this population. This was independent of the radiotherapy dose and 
added to the evidence towards consequential late effects [18,19]. Physical Health and Physical 
Function Clusters were important antecedents of symptoms at 3 years in older men. Older men are 
likely to have multiple underlying health problems and this may influence their physical and 
functional health [21,22]. Screening of health status and management of co-morbidities is important 
prior to treatment as this may improve fitness. This is recommended in the International Society of 
Geriatric Oncology (SIOG) guidance for older cancer patients [59]. Poorer fitness may be a 
consequence of an individual’s poorer health rather than chronological age alone. There is evidence 
that even small increase in physical activity such as walking (five hours of moderate intensity physical 
activity per week) can significantly reduce PCa specific mortality in men with low risk tumours [60] 
but this may not be the same in metastatic PCa [55].  
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Previous analysis of PROs from the MRC RT01 trial identified that gastrointestinal toxicity 
increased from baseline for up to 3 years post-radiotherapy [61]. Acute bladder symptoms were also a 
precursor of late symptoms and patients with pre-treatment bladder symptoms were more likely to 
report bladder symptom at 5 years [62]. Emerging evidence around phosphodiesterase type 5 (PDE5) 
inhibitors suggests that these agents may have an impact not only on sexual but also on urinary 
symptoms [63,64]. However, the clinical mechanisms of this effect remain unclear. Provision of 
support in the cancer recovery pathway, through survivorship plans, has mixed results in terms of 
benefits, but referral to voluntary sector services could improve self-management and early symptom 
support [65]. This reflects findings from other studies [66-68] and underpins the importance of 
employing a broader PROs assessment that includes symptoms, function and HRQOL measurements. 
If it is established that pre-treatment PROs scores predict poor post radiotherapy outcomes then there 
is a need to intervene and demonstrate through research that the consequences of cancer treatment can 
be prevented. Future work is needed to establish whether poor PROs and thus men’s long-term quality 
of life can be improved. 
Strengths and limitations  
 The strength of this study is that MRC RT01 is a large dataset with a long follow-up. PROs of 
PCa patients are recorded for 5 years following treatment and, unusually, the trial asked participants 
to complete multiple PRO. These data allowed us to observe the late deterioration in symptoms and 
HRQOL that starts to emerge from year 2 post-radiotherapy. This deterioration possibly due to 
radiation fibrosis deserves attention and engagement of early management strategies [69]. With the 
long-term follow-up we were also able to establish the effect of early outcomes on late PROs. These 
findings are important in the identification of patients at risk of late radiotherapy-related toxicity. The 
limitation of this study is the large number of trial participants not returning PROs at certain time 
points and the fact that clustering analysis and longitudinal profiles are presented for different number 
of patients at each point in time. In addition, UCLA-PCI is now an old tool that has largely been 
replaced in PCa health assessment by the Expanded Prostate Cancer Index Composite (EPIC) 
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instrument [70]. However, because EPIC adapts similar scoring rules for its items, investigating 
symptom clusters over time can be beneficial. 
 
CONCLUSIONS 
 This study uniquely contributes to the understanding of the consequences of cancer treatment 
and how symptom clusters can be used in supportive care of men before and after PCa radiotherapy. 
Early symptoms, older age, physical function and physical health were associated with the severity of 
late symptoms. Therefore, early management of age related co-morbidities and prehabilitation of 
physical and functional status by promoting physical activity, as well as guiding patients to support 
and counselling services, should complement treatment planning to aid recovery during and after 
radiotherapy. It has been shown here and in other PCa studies that age and pre-treatment health and 
function could be used to identify patients at greater risk of post-treatment symptoms [71]. Sub-
groups of patients who are likely to have poorer functional and HRQOL outcomes can be identified 
using PROs. This has been undertaken in women with breast cancer [72]. Early assessment using 
PROs and patient stratification that incorporates risk factors may help to identify men that require 
prehabilitation and additional support throughout their treatment and recovery. Furthermore, there is a 
need for more research studies that investigate the impact of personalised interventions to improve 
symptoms and long-term outcomes of radiotherapy patients.     
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Table 1. Medical Research Council RT01 study: patient baseline characteristics (N = 843) 
Characteristic Mean (SD) N % 
Radiotherapy treatment dose 
Standard 
Escalated 
  
421 
422 
 
50 
50 
Age (years) 67 (6)   
Stage 
T1 
T2 
T3 
Missing 
  
209  
475  
147  
12  
 
25 
56 
17 
1 
Gleason score 
2-4 
5-6 
7 
8-10 
Missing 
  
70  
411 
191  
96  
75  
 
8 
49 
23 
11 
9 
PSA (ng/ml)  
Missing  
15.4 (10) 
 
 
6  
 
1 
Diabetes  
Missing  
 55  
8  
6 
1 
Hypertension  
Missing  
 252  
8  
30 
1 
Inflammatory bowel or any diverticular disease  
Missing  
 36  
12  
4 
1 
Haemorrhoids in past 12 months 
Missing  
 89  
18  
11 
2 
Type of biopsy 
Transrectal 
TURP 
Other 
Missing  
  
715  
102  
19  
7  
 
85 
12 
2 
1 
Previous pelvic surgery  
Missing  
 48  
13  
6 
1 
Previous TURP  
Missing  
 100  
14 
12 
2 
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Table 2. Results of symptom clustering. Items collected with the UCLA-PCI and the SF-36 that belong to a 
cluster in a given point in time are shaded and marked with x in the table. Core cluster symptoms (present in 
clusters across time) are marked in bold. Symptoms never present in the symptom cluster are marked with *. 
Seven symptom clusters were identified: Physical Function, Physical Health, Emotional Health, Vitality, 
Illness Perception, Urinary Function and Sexual Function.  
 
Tool UCLA-PCI and SF-36 scales and items Point in time 
  P
re
-A
D
T
 (N
 =
 5
7
8
) 
P
re
-R
T
 (N
 =
 7
5
7
) 
W
ee
k
 1
0
 (N
 =
 7
3
8
) 
M
o
n
th
 6
 (N
 =
 7
1
2
) 
M
o
n
th
 1
2
 (N
 =
 6
8
9
) 
M
o
n
th
 1
8
 (N
 =
 6
5
5
) 
Y
ea
r 2
 (N
 =
 6
4
5
) 
Y
ea
r 3
 (N
 =
 5
9
4
) 
Y
ea
r 4
 (N
 =
 5
1
5
) 
Y
ea
r 5
 (N
 =
 4
2
5
) 
SF-36 Physical functioning  Physical Function Cluster  
 Vigorous activities*           
 Moderate activities x    x x     
 Lifting / carrying x    x x     
 Climbing several flights of stairs  x x  x  x x x x X 
 Climbing one flight of stairs  x x   x      
 Walking one mile x x x x x x x x x x 
 Walking several blocks x x x x x x x x x x 
 Walking one block x x x  x x     
 Bending / kneeling*           
 Bathing /dressing*           
SF-36 Role limitations due to physical health Physical Health Cluster  
 Cut down on activities x x x x x x x x x  
 Accomplished less  x x x x x x x x x x 
 Limited in kind of work x x x x x x x x x x 
 Difficulty working  x x x x x x x x x x 
SF-36 Role limitations due to emotional problems Emotional Health Cluster  
 Cut down on activities x x x x x x x x x x 
 Accomplished less  x x x x x x x x x x 
 Did not work as carefully  x x x x x x x   x 
SF-36 Vitality Vitality Cluster  
 Full of life   x x x x  x x  
 A lot of energy    x x x x  x x  
 Worn out   x x x x  x x  
 Feeling tired    x x x x  x x  
SF-36 General health  Illness Perception Cluster  
 Get sick easier*           
 As healthy as anyone  x x x x x x x x x x 
 Health is excellent  x x x x x x x x x x 
 Health in general  x x x x x x x x x x 
 Health get worse*           
PCI Urinary function  Urinary Function Cluster   
 Urinary leak  x x x x x x x x x x 
 Urinary control  x x x x x x x x x x 
 Dripping / wetting  x x x x x x x x x x 
 Number of pads or diapers*             
 Urinary leak interfering with sex*           
PCI Sexual function  Sexual Function Cluster  
 Sexual desire  x   x   x  x x 
 Erection ability x x x x x x x x x x 
 Orgasm ability x x x x x x x x x x 
 Quality of erections x x x x x x x x x x 
 Frequency of erections x x x x x x x x x x 
 Sexual function overall  x x x x x x x x x x 
 Awakened with erections    x x x  x x x 
 Intercourse*           
22 
 
 
Table 3. Multivariate mixed effects analyses show the contribution of potential risk factors to the 
changes in profiles of symptom clusters over time. A separate model was obtained for each of the 
symptom clusters: Physical Function, Physical Health, Emotional Health, Vitality, Illness Perception, 
Urinary Function and Sexual Function. Random effects included radiotherapy dose, time and 
individual patient variation. Fixed effects included baseline patient characteristics, medical history 
and other symptom clusters that were used as independent variables (potential risk factors). 
Independent variables with preliminary significant associations of p<0.05 were retained in the final 
regression models. A statistical significance level was set at p<0.01. 
 
Dependent 
variable  Independent variable  
Regression 
coefficient 
Standard 
error        95% CI p-value 
Physical 
Function 
Cluster 
Age (per 10 years) -3.64 1.10 -5.8 -1.49 0.001 
Hypertension (No) 3.69 1.41 0.93 6.44 0.009 
Physical Health 0.16 0.02 0.13 0.19 <0.001 
Vitality 0.22 0.04 0.15 0.29 <0.001 
Illness Perception 0.23 0.03 0.18 0.28 <0.001 
Urinary Function 0.06 0.03 0.01 0.11 0.014 
Physical 
Health 
Cluster 
Age (per 10 years) -5.61 1.18 -7.93 -3.29 <0.001 
Physical Function 0.26 0.03 0.21 0.31 <0.001 
Emotional Health 0.34 0.02 0.3 0.38 <0.001 
Vitality 0.81 0.04 0.74 0.88 <0.001 
Emotional 
Health 
Cluster 
Physical Health 0.37 0.02 0.32 0.41 <0.001 
Vitality 0.31 0.05 0.21 0.40 <0.001 
Illness Perception 0.12 0.03 0.05 0.19 0.001 
Urinary Function 0.11 0.03 0.04 0.17 0.001 
Sexual Function -0.05 0.02 -0.10 -0.01 0.034 
Vitality 
Cluster 
Age (per 10 years) 2.61 0.68 1.29 3.95 <0.001 
Physical Function 0.08 0.01 0.05 0.10 <0.001 
Physical Health 0.18 0.01 0.17 0.21 <0.001 
Emotional Health 0.07 0.01 0.05 0.09 <0.001 
Illness Perception 0.26 0.02 0.22 0.29 <0.001 
Urinary Function 0.05 0.02 0.02 0.08 0.002 
Sexual Function 0.06 0.01 0.04 0.08 <0.001 
Illness 
Perception 
Cluster 
Age (per 10 years) 3.13 1.02 1.11 5.11 0.002 
Stage -1.25 0.51 -2.25 -0.26 0.014 
Gleason score 1.22 0.47 0.31 2.13 0.009 
Hypertension (No) 4.73 1.31 2.17 7.30 <0.001 
Inflam. bowel (No) 7.06 3.12 0.96 13.17 0.024 
Physical Function 0.14 0.02 0.10 0.18 <0.001 
Vitality 0.49 0.03 0.44 0.54 <0.001 
Urinary 
Function 
Cluster   
Gleason score 1.24 0.49 0.29 2.20 0.011 
Emotional Health 0.04 0.01 0.02 0.07 0.002 
Vitality 0.12 0.03 0.07 0.18 <0.001 
Sexual Function 0.05 0.02 0.02 0.08 0.003 
Sexual 
Function 
Cluster 
Age (per 10 years) -11.95 1.24 -14.38 -9.52 <0.001 
Diabetes (No) 7.46 2.96 1.66 13.26 0.012 
Vitality 0.25 0.04 0.18 0.32 <0.001 
Illness Perception 0.10 0.03 0.04 0.17 0.001 
Urinary Function 0.08 0.03 0.02 0.14 0.008 
 
  
23 
 
Figure 1. Longitudinal profiles of symptom clusters. A) Physical Function Cluster, B) Physical 
Health Cluster, C) Emotional Health Cluster, D) Vitality Cluster, E) Illness Perception Cluster, F) 
Urinary Function Cluster and G) Sexual Function Cluster. A-E items from the SF-36. F and G items 
from the UCLA-PCI.  
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Figure 2. The time trajectory of symptom clusters during neoadjuvent ADT and radiotherapy 
treatment and 5 years follow-up. The role of symptom clusters and the mechanism of late 
radiotherapy morbidity including consequential late effects and other potential risk factors influencing 
acute and late symptoms and radiotherapy-related toxicity. 
 
 
